

## **Ongoing Disclosure Notice**

## **Disclosure of Directors and Senior Managers Relevant Interests**

The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash

value, describe the consideration:

Number of financial products to which the transaction related:

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and	
Name of listed issuer:	Abano Healthcare Group Limited
Date this disclosure made:	22 December 2020
Date of last disclosure:	6 September 2019
Director or senior manager giving disclosure	
Full name(s):	Dr Ginni MANSBERG
Name of listed issuer:	Abano Healthcare Group Limited
Name of related body corporate (if applicable):	Not applicable
Position held in listed issuer:	Director, ceased 22 December 2020
Summary of acquisition or disposal of relevant interest (excluding specified derivatives	5)
Class of affected quoted financial products:	Ordinary shares
Nature of the affected relevant interest(s):	Registered holder and discretionary beneficiary of
reacted relevant interest(s).	the Ginni Trust
For that relevant interest-	
Number held in class before acquisition or disposal:	10,266 ordinary shares
Number held in class after acquisition or disposal:	Nil
Current registered holder(s):	Dr Ginni Pty Limited as Trustee for Ginni Trust
Registered holder(s) once transfers are registered:	Adams NZ Bidco Limited
Summary of acquisition or disposal of specified derivatives relevant interest (if applica	ble)
Type of affected derivative:	Not applicable
Class of underlying financial products:	Not applicable
Details of affected derivative-	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	Not applicable
A statement as to whether the derivative is cash settled or physically settled:	Not applicable
Maturity date of the derivative (if any):	Not applicable
Expiry date of the derivative(if any):	Not applicable
The price specified in the terms of the derivative (if any):	Not applicable
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	Not applicable
For that derivative,-	
Parties to the derivative:	Not applicable
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	Not applicable
Details of transactions giving rise to acquisition or disposal	
Total number of transactions to which notice relates:	One
Details of transactions requiring disclosure-	
Date of transaction:	22 December 2020
Nature of transaction:	A scheme of arrangement as described in the Abanc Scheme Booklet (including Supplementary Scheme Booklet).
Name of any other party or parties to the transaction (if known):	Adams NZ Bidco Limited
(,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	

\$53,383.20 (\$5.20 per share)

10,266 ordinary shares

If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—

Whether relevant interests were acquired or disposed of during a closed period: No Whether prior written clearance was provided to allow the acquisition or disposal to proceed Not applicable during the closed period: Date of the prior written clearance (if any): Not applicable Summary of other relevant interests after acquisition or disposal: Class of quoted financial products: Nil Nature of relevant interest: Nil For that relevant interest,-Number held in class: Nil Nil Current registered holder(s): For a derivative relevant interest,-Type of derivative: Not applicable Details of derivative,-The notional value of the derivative (if any) or the notional amount of underlying financial Not applicable products (if any): A statement as to whether the derivative is cash settled or physically settled: Not applicable Maturity date of the derivative (if any): Not applicable Expiry date of the derivative (if any): Not applicable The price's specified terms (if any): Not applicable Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial Not applicable For that derivative relevant interest,-Parties to the derivative: Not applicable If the director or senior manager is not a party to the derivative, the nature of the relevant Not applicable interest in the derivative: Certification I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.

Signature of person authorised to sign on behalf of director or officer:

Date of signature:

Name and title of authorised person:

## 22 December 2020

Richard Keys

Chief Executive Officer

## Notes

Use this form to disclose all the acquisitions and disposals by a director or senior manager of a listed issuer, or of a related body corporate, or in specified derivatives. The disclosure must be made within—

- (a) 20 working days after the first acquisition or disposal disclosed in this notice if the acquisitions or disposals are of a kind referred to in section 297(2)(a) of the Financial Markets Conduct Act 2013; or
- (b) in any other case, 5 trading days after the first acquisition or disposal disclosed in this notice.